Impact of cytogenetics risk on outcome after reduced intensity conditioning allo-SCT from an HLA-identical sibling for patients with AML in first CR: A report from the acute leukemia working party of EBMT

Bone Marrow Transplantation

Volumn 47, Issue 11, 2012, Pages 1442-1447

  Chevallier, P ^a   Labopin, M ^b   Milpied, N ^c   Cornelissen, J J ^d   Blaise, D ^e   Petersen, E ^f   Sandstedt, A ^g   Goker, H ^h   Socie, G ⁱ   Rocha, V ⁱ   Mohty, M ^a  

^a NANTES UNIVERSITY HOSPITAL   (France)

^b HÔPITAL SAINT ANTOINE   (France)

^c HAUT LÉVÊQUE HOSPITAL   (France)

^d ERASMUS MEDICAL CENTER   (Netherlands)

^e INSTITUT PAOLI CALMETTES   (France)

^f UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^g LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

^h HACETTEPE UNIVERSITY   (Turkey)

ⁱ SAINT LOUIS HOSPITAL   (France)

Author keywords

Allo SCT; AML; CR; cytogenetics; RIC; sibling donor

Indexed keywords

ALEMTUZUMAB; BUSULFAN; THYMOCYTE ANTIBODY;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER MORTALITY; CANCER PROGNOSIS; CANCER SURVIVAL; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; CYTOGENETICS; DISEASE FREE SURVIVAL; ENGRAFTMENT; FEMALE; GENETIC ASSOCIATION; GENETIC RISK; HUMAN; LEUKEMIA RELAPSE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; RECURRENCE RISK; REDUCED INTENSITY CONDITIONING; RISK ASSESSMENT; SURVIVAL TIME; WHOLE BODY RADIATION;

ADOLESCENT; ADULT; AGED; CYTOGENETICS; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HLA ANTIGENS; HUMANS; LEUKEMIA, MYELOID, ACUTE; LIVING DONORS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS; SIBLINGS; TRANSPLANTATION CONDITIONING; YOUNG ADULT;

EID: 84869094943     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2012.55     Document Type: Article

References (22)

1. Lowenberg B, Downing JR, Burnett A. Acute myeloid leukemia. N Engl J Med 1999; 341: 1051-1062. (Pubitemid 29451802)
2. Dö hner H, Estey EH, Amadori S, Appelbaum FR, Bü chner T, Burnett AK et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2010; 115: 453-474.
3. Blaise D, Vey N, Faucher C, Mohty M. Current status of reduced intensity conditioning allogeneic stem cell transplantation for acute myeloid leukemia. Haematologica 2007; 92: 533-541. (Pubitemid 350147795)
4. Ringden O, Labopin M, Ehninger G, Niederwieser D, Olsson R, Basara N et al. Reduced intensity conditioning compared with myeloablative conditioning using unrelated donor transplants in patients with acute myeloid leukemia. J Clin Oncol 2009; 27: 4570-4577.
5. Gyurkocza B, Storb R, Storer BE, Chauncey TR, Lange T, Shizuru JA et al. Nonmyeloablative allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia. J Clin Oncol 2010; 28: 2859-2867.
6. Grimwade D, Hills RK, Moorman AV, Walker H, Chatters S, Goldstone AH et al. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood 2010; 116: 354-365.
7. Bacigalupo A, Ballen K, Rizzo D, Giralt S, Lazarus H, Ho V et al. Defining the intensity of conditioning regimens: Working definitions. Biol Blood Marrow Transplant 2009; 15: 1628-1633.
8. Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HLA-matched sibling donors. Transplantation 1974; 18: 295-304.
9. Shulman H, Sullivan KM, Weiden PL, McDonald GB, Striker GE, Sale GE et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med 1980; 69: 204-217. (Pubitemid 10036817)
10. Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med 1999; 18: 695-706. (Pubitemid 29126745)
11. Burnett AK, Milligan D, Goldstone A, Prentice A, McMullin MF, Dennis M et al. The impact of dose escalation and resistance modulation in older patients with acute myeloid leukaemia and high-risk myelodysplastic syndrome: the results of the LRF AML14 trial. Br J Haematol 2009; 145: 318-332.
12. Pigneux A, Harousseau JL, Witz F, Sauvezie M, Bene MC, Luquet I et al. Addition of lomustine to idarubicin and cytarabine improves the outcome of elderly patients with de novo acute myeloid leukemia: a report from the GOELAMS. J Clin Oncol 2010; 28: 3028-3034.
13. Rö lling C, Thiede C, Gramatzki M, Aulitzky W, Bodenstein H, Bornhaü ser M et al. A novel prognostic model in elderly patients with acute myeloid leukemiaresults of 909 patients entered into the prospective AML96 trial. Blood 2010; 116: 971-978.
14. Rowe JM, Tallman MS. How I treat acute myeloid leukemia. Blood 2010; 116: 3147-3156.
15. Yacoub-Agha I, Mesnil F, Kuentz M, Boiron JM, Ifrah N, Milpied N et al. Allogeneic marrow stem-cell transplantation from human leukocyte antigen-identical siblings versus human leukocyte antigen-allelic-matched unrelated donors (10/10) in patients with standard-risk hematologic malignancy: a prospective study from the French Society of Bone Marrow Transplantation and Cell Therapy. J Clin Oncol 2006; 24: 5695-5702. (Pubitemid 46631311)
16. Moore J, Nivison-Smith I, Goh K, Ma D, Bradstock K, Szer J et al. Equivalent survival for sibling and unrelated donor allogeneic stem cell transplantation for acute myelogeneous leukemia. Biol Blood Marrow Transplant 2007; 13: 601-607. (Pubitemid 46585933)
17. Lioure B, Delaunay J, Blaise D, Milpied N, Guardiola P, Cahn JY et al. Allogeneic stem cell transplantation (SCT) with non myeloablative conditioning regimen (NST) following intensive consolidation may be equivalent to conventional alloSCT and superior to autoSCT for patients over 50 with acute myeloid leukemia (AML) in first CR: first results of the AML 2001 trial. Blood (ASH annual meeting abstracts) 2006; 108: p99a, Abstract 319.
18. Aoudjhane M, Labopin M, Gorin NC, Shimoni A, Ruutu T, Kolb HJ et al. Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: a retrospective survey from the Acute Leukaemia Working Party (ALWP) of the European group for Blood and Marrow Transplantation (EBMT). Leukemia 2005; 19: 2304-2312. (Pubitemid 41748028)
19. Chevallier P, Szydlo RM, Blaise D, Tabrizi R, Michallet M, Uzunov M et al. Reducedintensity conditioning before allogeneic hematopoietic stem cell transplantation in patients over 60 years: a report from the SFGM-TC. Biol Blood Marrow Transplant 2012; 18: 289-294.
20. Prebet T, Boissel N, Reutenauer S, Thomas X, Delaunay J, Cahn JY et al. Acute myeloid leukemia with translocation (8;21) or inversion (16) in elderly patients treated with conventional chemotherapy: a collaborative study of the French CBF-AML intergroup. J Clin Oncol 2009; 27: 4747-4753.
21. Kirschbaum MH, Stein AS, Popplewell L, Delioukina M, Chen R, Nakamura R et al. A phase I study in adults of Clofarabine combined with high-dose Melphalan as reduced-intensity conditioning for allogeneic transplantation. Biol Blood Marrow Transplant 2012; 18: 432-440.
22. +) T-cell immunity against cancer-testis antigens develops following allogeneic stem cell transplantation and reveals a potential mechanism for the graft-versusleukemia effect. Haematologica 2010; 95: 1572-1578.